Status:
UNKNOWN
CTC Changes and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer
Lead Sponsor:
Shengjing Hospital
Conditions:
Breast Neoplasms
Eligibility:
FEMALE
18-60 years
Brief Summary
Chemotherapy before operation for malignant tumors can reduce the size of tumors to a certain extent, even eliminate micrometastases. Chemotherapy can also detect the sensitivity of chemotherapeutic d...
Detailed Description
Triple-negative breast cancer refers to breast cancer with negative human epidermal growth factor receptor 2, estrogen receptor and progesterone receptor. Triple-negative breast cancer has poor differ...
Eligibility Criteria
Inclusion
- triple-negative breast cancer confirmed by breast biopsy;
- stage III breast cancer (IIIA-C) assessed by CT or MRI;
- neoadjuvant chemotherapy;
- informed consent of patients and their family members.
Exclusion
- use of second-line chemotherapy regimen;
- bilateral breast cancer;
- inflammatory breast cancer;
- pregnant or breast-feeding;
- distant metastasis;
- a history of other cancers or chest radiotherapy;
- a history of abnormal blood test or other infectious symptoms.
Key Trial Info
Start Date :
November 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 31 2024
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04059003
Start Date
November 1 2019
End Date
August 31 2024
Last Update
January 20 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute
Shengyang, Liaoning, China, 110042
2
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China, 110004